Pembrolizumab Achieves Response and Increased Survival in Melanoma

Pembrolizumab Achieves Response and Increased Survival in Melanoma
Pembrolizumab Achieves Response and Increased Survival in Melanoma

Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial. The 12-month progression-free survival rate was 35% and the median overall survival was 23 months.1

This phase 1b trial pooled data from 655 enrolled patients to analyze safety and efficacy. The median duration of follow-up was 21 months. The study was performed in medical centers in Australia, Canada, France, and the United States.

Immune system responses to melanoma are limited by the programmed death 1 (PD-1) pathway, which can be blocked by the humanized anti-PD-1 monoclonal antibody pembrolizumab.

This analysis measured objective response rate, which was best overall response of complete or partial response. The objective response rate was 33%.

Median survival was 23 months in the total population (95% CI, 20-29 months) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naïve patients, median survival was 31 months (95% CI, 24 to not reached), the 12-month survival rate was 73% (95% CI, 65%-79%), and the 24-month survival rate was 60% (95% CI, 51%-68%).

Grade 3 or 4 adverse events occurred in 14% of patients. Treatment was discontinued in 4% of patients because of a treatment-related adverse event. No drug-related deaths occurred.

An accompanying editorial noted that challenges remain for treating metastatic melanoma with a PD-1 blockade.2 Biomarkers need to be identified. The overall efficacy indicates that anti-PD-1 monotherapy has limitations for advanced melanoma, as the 12-month progression-free survival rate was only 35% and even among patients who responded, 26% experienced disease progression.

References

1.Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600-1609. doi:10.1001/jama.2016.4059.

2. Bhatia S, Thompson JA. PD-1 blockade in melanoma: a promising start, but a long way to go. JAMA. 2016;315(15):1573-1575. doi:10.1001/jama.2016.4012.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs